New nasal spray could help those with stubborn depression

NCT ID NCT07053345

Completed Disease control Sponsor: Janssen Korea, Ltd., Korea Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests esketamine nasal spray in 47 Korean adults with treatment-resistant depression (depression that hasn't improved with other treatments). Participants will use the spray themselves twice a week for 4 weeks. The main goal is to see if depressive symptoms improve, measured by a standard depression scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: esketamine nasal spray
What this could lead to: If it works, this could offer a new option for people with depression that hasn't improved with other treatments.
What could go wrong: This is a small, early-phase study with only 47 participants, so results may not apply to everyone. Esketamine can cause side effects like dizziness, nausea, or dissociation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, TREATMENT-RESISTANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

depressive disorder Depressive Disorder, Treatment-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSIVE DISORDER, TREATMENT-RESISTANT

Contacts and locations

Locations

Asan Medical Center

Seoul, 05505, South Korea
Cha Ilsan Medical Center

Goyang Si Gyeonggi Do, 10414, South Korea
Kangbuk Samsung Hospital

Seoul, 03181, South Korea
Kyung Hee University Hospital

Seoul, 130 050, South Korea
Samsung Medical Center

Seoul, 06351, South Korea
Wonkwang University Hospital

Iksan, 570 711, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.